15-16 May 2007Geertrui Van OverwalleEUPACO One size fits all? How unitary is the present European patent system? Geertrui Van Overwalle Centre for Intellectual.

Slides:



Advertisements
Similar presentations
Ethical aspects and Patents in Lifescience Peter R. Thomsen Manager Global IP Litigation, Corporate Intellectual Property, Novartis WIPO symposium on IP.
Advertisements

Innovation - Lab National Institute for Standardization And Industrial Property Patenting procedure Overview.
Institut der beim Europäischen Patentamt zugelassenen Vertreter Institute of Professional Representatives before the European Patent Office Institut des.
Industrial Property the Patent system
Intellectual Property Rights (IPR)
Selected Cases on Patents and Biotechnology WIPO-UKRAINE SUMMER SCHOOL ON INTELLECTUAL PROPERTY – JULY 2011.
Interface between patent and sui generis systems of protection of plant varieties The 1978 UPOV Act does not allow both systems to be applied to the same.
THE PROTECTION OF INDUSTRIAL PROPERTY AND TREATIES ADMINISTERED BY WIPO TK.
Invention Spotting – Identifying Patentable Inventions Martin Vinsome June 2012.
The patentability of biotechnological inventions: The European Commission’s second 16c report Paul Van den Bulck Partner at Ulys Law Firm (Brussels) Lecturer.
Ownership and distribution Ethical issues in patenting Pr Samia Hurst Institute for Biomedical Ethics University of Geneva Medical School.
Ethics of Patents in Stem Cell Research
The European legal framework for patentability and regulation of stem cells : focus on Germany, Spain and France Paul Van den Bulck Partner at Ulys Law.
20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.
Ethics and Patents Gwilym Roberts Partner, Kilburn & Strode Kilburn & Strode LLP | 20 Red Lion Street | London | WC1R 4PJ | United Kingom T: +44.
Patents Southwest Quantum Technologies Group Richard Tatham 02/02/2015.
The patentability of human pluripotent embryonic stem cells and stem cell lines Paul Van den Bulck Partner at Ulys Law Firm (Brussels) Lecturer at the.
Rodolphe Bauer, Frédéric Dedek, Gareth Jenkins, Cristina Margarido
Intellectual Property – The Basics Christine Helliwell, PhD Scottish Health Innovations Ltd 25 th October 2012.
W HAT CAN BE PATENTED – AND WHAT DOES THAT MEAN ? András Jókúti Hungarian Intellectual Property Office Ankara, 25 January 2011.
SAREE AONGSOMWANG Foundation for Consumers, Thailand.
Patent Protection in Europe
INTELLECTUAL PROPERTY AND YOUR RIGHTS Helen Johnstone Seminar 12 July 2006 EAST MIDLANDS INTERNATIONAL TRADE ASSOCIATION.
1 American University Thursday 21 February 2013 Patents and the right to health Duncan Matthews Centre for Commercial Law Studies Queen Mary, University.
 Synthetic Biology: Caught between Property Rights, the Public Domain, and the Commons Arti Rai and James Boyle Presented by Pei-Ann Lin May 11, 2011.
Judicially Created Diversity in Patent Law Norman Siebrasse Professor of Law University of New Brunswick, Canada.
“Inventing the Future” – The Role of Utility Models and Patents in Leveraging Technical Innovation in the Market Place Kingston, Jamaica Jun 4 - 6, 2012.
Page 1 IOP Genomics Workshop Patents and Patenting Biotech Inventions Annemieke Breukink, Ph.D. September 8th, 2009.
Knowledge Transfer | Accelerating Innovation KT Training – 9 September 2014 Introduction to Intellectual Property Rights D. Mazur – 9 September 2014.
Seminar Industrial Property Protection Prague, 4 June 2003 Patent Protection in Europe Heidrun Krestel Liaison Officer Member States Co-operation Programmes.
Introduction to Patents Anatomy of a Patent & Procedures for Getting a Patent Margaret Hartnett Commercialisation & IP Manager University.
Intellectual Property Law © 2007 IBM Corporation EUPACO 2 – The European Patent Conference 16 May 2007 Patent Quality Roger Burt IBM Europe.
Intellectual Property: Patent Eligible Subject Matter Prof. Peng
A: Copy –Rights – Artistic, Literary work, Computer software Etc. B: Related Rights – Performers, Phonogram Producers, Broadcasters etc. C: Industrial.
© J. Straus Patenting of Genes and Life Forms, and the impact of Patenting on Upstream Science Joseph Straus, Munich WIPO Open Forum on the Draft.
Intellectual Property Legal Implications. What is Intellectual Property? The product of creativity and intellectual endeavour Intellectual Property Rights.
Patentable Subject Matter Donald M. Cameron. 2 Patents: The Bargain Public: gets use of invention after patent expires Inventor/Owner: gets limited monopoly.
1 Patent Claim Interpretation under Art. 69 EPC – Should prosecution history be used to interpret the patent? presented at Fordham 19th Annual Conference.
© 2004 The IPR-Helpdesk is a project of the European Commission DG Enterprise, co-financed within the fifth framework programme of the European Community.
Selected Contemporary Issues in Field of Patents WIPO-UKRAINE SUMMER SCHOOL ON INTELLECTUAL PROPERTY – JULY 2011.
Intellectual Property Law Introduction Victor H. Bouganim WCL, American University.
Lecture 27 Intellectual Property. Intellectual Property simply defined is any form of knowledge or expression created with one's intellect. It includes.
PATENTS, INTEGRATED CIRCUITS, AND INDUSTRIAL DESIGNS Presented By: Navdeep World Trade Organization.
Intellectual Property Law Unit Four. Patent Right Unit Four.
Patent Review Overview Summary of different types of Intellectual Property What is a patent? Why would you want one? What are the requirements for patentability?
ip4inno Module 5B IP in the real world Practical exercise to help you decide ‘What Protection is Appropriate?’ Name of speakerVenue & date.
Funding and patentability of stem cell research in the European Union - A critical legal review of European legislation Dr. Malene Rowlandson, University.
Patents in Russia Vladimir Biriulin, Partner Gorodissky and Partners Law Firm, Moscow, Russia.
Patent filing and tips on patent drafting Makerere University – July 7, 2016 Kagwa John Marius – Examiner Patents.
Ip4inno 1 Content of the module IP for the creative industries Patented computer-implemented inventions Software Biotechnological inventions.
Copyright Vs Patent Software authors lost their rights Benjamin Henrion Knowright2008 Krakow, 19 September 2008.
AIPLA Spring Meeting, Houston Texas
Overview of presentation
Key Aspects of Intellectual Property Knowledge Assets in Academia
Intellectual Property & Contemporary Issues of Biotechnology Law
The position in the UK Dr Ali Al-Alfatlawi.
Susy Frankel Victoria University of Wellington New Zealand
INTELLECTUAL PROPERTY RIGHTS
From Invention to Patent
Comparing subject matter eligibility in us and eu
The IP International framework Seminar on the Role of IP for SMEs Damascus, November 17 and 18, 2008 Marco Marzano de Marinis, Program Officer.
Chinese Patent Validation in Cambodia: How & Why
Patentable Subject Matter
GENERAL INTRODUCTION THE PATENT SYSTEM.
INTELLECTUAL PROPERTY RIGHTS
TRIPS Art. 27.3(b) and Agriculture
Trilateral Seminar of the French, German and Polish Groups of AIPPI
Influence of AI creations on the IP rules
Patentable Subject Matter in Korea
Presentation transcript:

15-16 May 2007Geertrui Van OverwalleEUPACO One size fits all? How unitary is the present European patent system? Geertrui Van Overwalle Centre for Intellectual Property Rights, K.U.Leuven, Belgium EUPACO Brussels, May 2007 K.U.Leuven

15-16 May 2007Geertrui Van OverwalleEUPACO Overview Take stock European framework with regard to Eligible subject matter Patentability requirements Scope of protection Exercise of rights Patent term of differentiation [which is technology specific]

15-16 May 2007Geertrui Van OverwalleEUPACO Eligible subject matter General rule –art. 52 (1) EPC “European patents shall be granted for any inventions which are susceptible of industrial application, which are new and which involve an inventive step” End of differentation?

15-16 May 2007Geertrui Van OverwalleEUPACO Exclusion of inventions –Too abstract in nature discoveries, scientific theories and mathematical methods (article 52-2)[NEL!] –Non technical in nature [technology specific] aesthetic creations; schemes, rules and methods for performing mental acts, playing games or doing business, and programs computers; presentation of information (art.52-2) [NEL!] –Policy [health] reasons methods for treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human and animal body (article 52-4) –Ethical reasons [technology specific] invention s the publication or exploitation of which would be contrary to ‘OP' or morality processes for cloning human beings;processes for modifying the germ line genetic identity of human beings; uses of human embryos for industrial or commercial purposes [NEL!] human embryonic stem cells? (article 53 a + Rule 23) –Legal reasons [prohibition double protection]: plant and animal varieties (article 53 b) Differentation! Non-exclusive lists + interpretation problems = legal uncertainty. Do we need more?

15-16 May 2007Geertrui Van OverwalleEUPACO Patentability requirements General rule –art. 52 (1) EPC “European patents shall be granted for any inventions which are susceptible of industrial application, which are new and which involve an inventive step” Differentiation –Inventive step –“person skilled in the art” in the respective field of technology –Disclosure requirement –Somewhat looser in the field of software? Hardly any differentation! Do we want more?

15-16 May 2007Geertrui Van OverwalleEUPACO Scope of protection General rule –Article 69 EPC –Article 69 (1) EPC: ‘The extent of the protection conferred by a European patent or a European patent application shall be determined by the terms of the claims” –Protocol on the Interpretation of Article 69 EPC: “Article 69 should be interpreted as defining a position which combines a fair protection for the patentee with a reasonable degree of certainty for third parties.”

15-16 May 2007Geertrui Van OverwalleEUPACO Scope of protection Application Article 69 Differentation! Not desirable – we want reduce it!

15-16 May 2007Geertrui Van OverwalleEUPACO Deviations –Technology specific: genetics: absolute protection/purpose bound protection Germany France –Differentation! Is it legitimate? Scope of protection

15-16 May 2007Geertrui Van OverwalleEUPACO Exercise of rights General practice –Exploitation –Licensing/cross licensing Models facilitating licensing –Conventional models: “license of right” The patent proprietor files a written statement with the patent authority that he is prepared to allow any person to use the invention as a licensee in return for appropriate compensation. In that case, a reduction of annual fees will be applied. CPC (art. 20) German Patent Act (art. 23). Between 1949 – 2002 more than statements [Krasser]. Effect on subsequent licensing relations? Differentation! Further research needed! –New models: collaborative rights management Success is technology related –ICT: successful [industry standard] –Genetics: difficult, cumbersome [incentive?]

15-16 May 2007Geertrui Van OverwalleEUPACO Exercise of rights Differentation desirable! How to realize? VAN ZIMMEREN, E., VERBEURE, B., MATTHIJS, G., & VAN OVERWALLE, G., ‘A Clearinghouse for Diagnostic Testing: the Solution to Ensure Access to and Use of Patented Genetic Inventions?’, Bulletin of the World Health Organization, 2006,

15-16 May 2007Geertrui Van OverwalleEUPACO Collaborative rights mechanisms: ‘markets for lemons’? Prof. Dirk Czarnitzky Patent licensing in human genetics within the European Union: a survey on common and new licensing approaches Drs. Esther van Zimmeren, LLM Exercise of rights

15-16 May 2007Geertrui Van OverwalleEUPACO Exercise of rights Limitations. Compulsory licenses –Non technology specific Non use Dependancy –Technology specific Public health Differentation! Do we want more?

15-16 May 2007Geertrui Van OverwalleEUPACO Patent term General rule High quality [inv st], fully fletched patent: 20 years High cost Alternative –Conventional alternative: “petty patent” “utility model” “Gebrauchsmuster” “Lower” quality [inv st], restricted patent: 6 years Lower cost Differentation! Technology tailored? [Life cycle product] –New alternative: “social patent” [High quality] Low/No cost No use for exclusionairy commercial purposes [Arti RAI & James BOYLE, Synthetic Biology: Caught between Property Rights, the Public Domain and the Commons, PLoS, March 2007] Differentation use of the patent – Welcome! Feasible?

15-16 May 2007Geertrui Van OverwalleEUPACO Conclusion 1.Eligible subject matter : Differentation! Non-exclusive lists + interpretation problems! Do we need more? 2.Patentability requirements Hardly any differentation! Do we want more? 3.Scope of protection Application Protocol: Differentation! Not desirable – we want reduce it! Purpose bound: Differentation! Is it legitimate? Do we want to apply it beyond genetics? 4.Exercise of rights “License of right”: Differentation! Further research needed! Collaborative rights models: Differentation desirable! How to realize? Limitation of rights (compulsory licensing): Differentation! Do we want more? 5.Patent term Petty patents: Differentation! Technology tailored? [Life cycle product] Social patents: Welcome – feasible?